Drug intelligence / Profile preview

SNK02

Development stage: Phase 1
Lead developer: NKGen Biotech, Inc.
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SNK02 is an allogeneic, blood-derived natural killer (NK) cell therapy being developed by NKGen Biotech for the treatment of solid tumors. Unlike its autologous counterpart SNK01, SNK02 is derived from healthy donors, allowing for potential off-the-shelf administration. The therapy is designed to leverage the innate cytotoxic capabilities of NK cells to target and eliminate cancer cells. NKGen Biotech holds the exclusive license for SNK02 in markets outside of Asia from NKMax. It is currently in Phase 1 clinical development for patients with pathologically confirmed cancer refractory to conventional therapy.

Other names: allogeneic NK cell therapy

Beyond the preview

Go deeper on SNK02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNK02.

Explore the full profile